

Diane M Simeone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/68131/publications.pdf>

Version: 2024-02-01

50
papers

6,917
citations

201674

27
h-index

197818

49
g-index

54
all docs

54
docs citations

54
times ranked

11028
citing authors

#	ARTICLE	IF	CITATIONS
1	Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity.. Journal of Clinical Oncology, 2022, 40, 190-190.	1.6	2
2	BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy.. Journal of Clinical Oncology, 2022, 40, TPS2676-TPS2676.	1.6	0
3	Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut, 2021, 70, 743-760.	12.1	49
4	ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer. Genes and Development, 2021, 35, 218-233.	5.9	23
5	Cancer surveillance awareness and practice among families at increased risk for pancreatic adenocarcinoma. Cancer, 2021, 127, 2271-2278.	4.1	5
6	Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis. Nature Communications, 2021, 12, 2047.	12.8	30
7	The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes and Development, 2021, 35, 940-962.	5.9	51
8	Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer. Scientific Reports, 2021, 11, 12491.	3.3	1
9	Proteome heterogeneity and malignancy detection in pancreatic cyst fluids. Clinical and Translational Medicine, 2021, 11, e506.	4.0	2
10	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut, 2020, 69, 7-17.	12.1	357
11	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. Ca-A Cancer Journal for Clinicians, 2020, 70, 375-403.	329.8	237
12	Needle-compatible miniaturized optoelectronic sensor for pancreatic cancer detection. Science Advances, 2020, 6, .	10.3	5
13	Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy. Molecular Cancer Therapeutics, 2020, 19, 1308-1319.	4.1	33
14	Metabolic Regulation of Redox Balance in Cancer. Cancers, 2019, 11, 955.	3.7	80
15	A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tff Pancreatic Cancer. Journal of Pancreatic Cancer, 2019, 5, 35-42.	0.9	10
16	ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis. Genes and Development, 2019, 33, 641-655.	5.9	20
17	New Labyrinth Microfluidic Device Detects Circulating Tumor Cells Expressing Cancer Stem Cell Marker and Circulating Tumor Microemboli in Hepatocellular Carcinoma. Scientific Reports, 2019, 9, 18575.	3.3	38
18	ATDC mediates a TP63-regulated basal cancer invasive program. Oncogene, 2019, 38, 3340-3354.	5.9	17

#	ARTICLE	IF	CITATIONS
19	Pancreatic Microtumors: A Novel 3D Ex Vivo Testing Platform. <i>Methods in Molecular Biology</i> , 2019, 1882, 73-80.	0.9	5
20	Low dose photodynamic therapy harmonizes with radiation therapy to induce beneficial effects on pancreatic heterocellular spheroids. <i>Oncotarget</i> , 2019, 10, 2625-2643.	1.8	31
21	An academic career in global surgery: a position paper from the Society of University Surgeons Committee on Academic Global Surgery. <i>Surgery</i> , 2018, 163, 954-960.	1.9	34
22	Profiling Heterogeneous Circulating Tumor Cells (CTC) Populations in Pancreatic Cancer Using a Serial Microfluidic CTC Carpet Chip. <i>Advanced Biology</i> , 2018, 2, 1800228.	3.0	13
23	HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. <i>ELife</i> , 2018, 7, .	6.0	51
24	SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. <i>Cancer Discovery</i> , 2018, 8, 1237-1249.	9.4	216
25	Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. <i>Gut</i> , 2017, 66, 124-136.	12.1	269
26	Microfluidic continuum sorting of sub-populations of tumor cells via surface antibody expression levels. <i>Lab on A Chip</i> , 2017, 17, 1349-1358.	6.0	26
27	High-Throughput Microfluidic Labyrinth for the Label-free Isolation of Circulating Tumor Cells. <i>Cell Systems</i> , 2017, 5, 295-304.e4.	6.2	88
28	Localized Pancreatic Cancer: Multidisciplinary Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e217-e226.	3.8	23
29	GM-CSF Mediates Mesenchymal-Épithelial Cross-talk in Pancreatic Cancer. <i>Cancer Discovery</i> , 2016, 6, 886-899.	9.4	156
30	A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2016, 34, 733-739.	2.6	31
31	Opportunities and Challenges for Pancreatic Circulating Tumor Cells. <i>Gastroenterology</i> , 2016, 151, 412-426.	1.3	60
32	ATDC (Ataxia Telangiectasia Group D Complementing) Promotes Radioresistance through an Interaction with the RNF8 Ubiquitin Ligase. <i>Journal of Biological Chemistry</i> , 2015, 290, 27146-27157.	3.4	17
33	Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism. <i>Carcinogenesis</i> , 2015, 36, 730-738.	2.8	29
34	Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma. <i>Laboratory Investigation</i> , 2015, 95, 43-55.	3.7	44
35	Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. <i>Oncotarget</i> , 2014, 5, 12383-12397.	1.8	175
36	Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 5937-5945.	7.0	255

#	ARTICLE	IF	CITATIONS
37	A Pilot Study of Diffusion-Weighted MRI in Patients Undergoing Neoadjuvant Chemoradiation for Pancreatic Cancer. <i>Translational Oncology</i> , 2014, 7, 644-649.	3.7	63
38	In vivo optical spectroscopy for improved detection of pancreatic adenocarcinoma: a feasibility study. <i>Biomedical Optics Express</i> , 2014, 5, 9.	2.9	15
39	Post-brushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: The Papanicolaou Society of Cytopathology Guidelines. <i>CytoJournal</i> , 2014, 11, 40.	1.7	5
40	Clinical evaluation, imaging studies, indications for cytologic study and preprocedural requirements for duct brushing studies and pancreatic fine-needle aspiration: The Papanicolaou Society of Cytopathology Guidelines. <i>CytoJournal</i> , 2014, 11, 1.	1.7	22
41	Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells. <i>Gastroenterology</i> , 2014, 147, 1393-1404.	1.3	529
42	The Notch Pathway Is Important in Maintaining the Cancer Stem Cell Population in Pancreatic Cancer. <i>PLoS ONE</i> , 2014, 9, e91983.	2.5	138
43	Characterizing human pancreatic cancer precursor using quantitative tissue optical spectroscopy. <i>Biomedical Optics Express</i> , 2013, 4, 2828.	2.9	23
44	Protein Kinase A Modulates Transforming Growth Factor- β 2 Signaling through a Direct Interaction with Smad4 Protein. <i>Journal of Biological Chemistry</i> , 2013, 288, 8737-8749.	3.4	24
45	Bmi1 Enhances Tumorigenicity and Cancer Stem Cell Function in Pancreatic Adenocarcinoma. <i>PLoS ONE</i> , 2013, 8, e55820.	2.5	94
46	c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target. <i>Gastroenterology</i> , 2011, 141, 2218-2227.e5.	1.3	333
47	SSAT/AGA/ASGE State of the Art Conference on Cystic Neoplasms of the Pancreas. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 1475-1477.	1.7	14
48	CEACAM1, a Novel Serum Biomarker for Pancreatic Cancer. <i>Pancreas</i> , 2007, 34, 436-443.	1.1	137
49	Identification of Pancreatic Cancer Stem Cells. <i>Cancer Research</i> , 2007, 67, 1030-1037.	0.9	3,017
50	Islet hypertrophy following pancreatic disruption of Smad4 signaling. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 291, E1305-E1316.	3.5	20